Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
- 9 December 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (5) , 734-738
Abstract
We investigated the short‐term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight ( BMI ≥25 kg/m 2 ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24‐week double‐blinded, placebo‐controlled trial. At baseline and after 24 weeks of treatment, 24‐hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima‐media thickness were evaluated. Compared with placebo, liraglutide increased 24‐hour heart rate by 4.6 beats per minute ( BPM ); P = .0015, daytime heart rate by 3.7; P = .0240 and night‐time heart rate by 7.5 BPM ; P < .001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg ; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long‐standing type 1 diabetes, liraglutide as add‐on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.Keywords
Funding Information
- Boehringer Ingelheim
- Gilead Sciences
- Novartis Pharma
- AstraZeneca
- Roche
This publication has 16 references indexed in Scilit:
- Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2016
- Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel StudyDiabetes Care, 2015
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 studyBMJ Open, 2015
- The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systemsDiabetes, Obesity and Metabolism, 2014
- Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage StudyPLOS Medicine, 2012
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 DiabetesDiabetes Care, 2007
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic IndividualsJAMA, 2001
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993